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Abstract
Background: Epstein-Barr virus (EBV) was the first virus identified to encode microRNAs (miRNAs). Both of viral and
human cellular miRNAs are important in EBV infection. However, the dynamic expression profile of miRNAs during
primary EBV infection was unknown. This study aimed to investigate the dynamic expression profile of viral and
cellular miRNAs in infectious mononucleosis (IM) caused by primary EBV infection.
Methods: The levels of viral and cellular miRNAs were measured in fifteen pediatric IM patients at three different
time-points. Fifteen healthy children who were seropositive for EBV were enrolled in the control group. Relative
expression levels of miRNAs were detected by quantitative real-time PCR (qPCR) assay.
Results: EBV-miR-BHRF1-1, 1-2-3P, miR-BART13-1, 19-3p, 11-3P, 12–1, and 16–1 in IM patients of early phase were
significantly higher than in healthy children. Most cellular miRNAs of B cells, such as hsa-miR-155-5p, −34a-5p, −18b-5p,
−181a-5p, and −142-5p were up-regulated; while most of cellular miRNAs of CD8 + T cells, such as hsa-miR-223, −29c-
3p, −181a, −200a-3p, miR-155-5p, −146a, and −142-5p were down-regulated in IM patients. With disease progression,
nearly all of EBV-miRNAs decreased, especially miR-BHRF1, but at a slower rate than EBV DNA loads. Most of the cellular
miRNAs of B cells, including hsa-miR-134-5p, −18b-5p, −34a-5p, and -196a-5p increased with time. However, most of
the cellular miRNAs of CD8 + T cells, including hsa-let-7a-5p, −142-3p, −142-5p, and −155-5p decreased with time.
Additionally, hsa-miR-155-5p of B cells and hsa-miR-18b-5p of CD8+ T cells exhibited a positive correlation with
miR-BHRF1-2-5P and miR-BART2-5P (0.96 ≤ r ≤ 0.99, P < 0.05). Finally, hsa-miR-181a-5p of B cells had positive
correlation with miR-BART4-3p, 4-5P, 16–1, and 22 (0.97 ≤ r ≤ 0.99, P < 0.05).
Conclusions: Our study is the first to describe the expression profile of viral and cellular miRNAs in IM caused by
primary EBV infection. These results might be the basis of investigating the pathogenic mechanism of EBV-related
diseases and bring new insights into their diagnosis and treatment.
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Background
Epstein-Barr virus (EBV), an oncogenic virus of gamma
herpes family, infects over 95 % of people worldwide. B
lymphocytes are the target cells in primary EBV infection.
Most children with primary EBV infection are asymptom-
atic, but some children can manifest as infectious mono-
nucleosis (IM). IM is a self-limited disease which is due to
the transient proliferation of EBV-infected B cells accom-
panied by excessive response of EBV-specific cytotoxic T
cells (CTL) [1]. A previous study [2] showed a positive
correlation between the levels of CD8+ T cells and NK
cells and the severity of IM. After acute phase, EBV drives
the proliferation and differentiation of the naïve B cells
into memory B cells and persists for the life of the host in
a latent state in the memory B cells. This could allow EBV
to escape immune recognition and prevent immune-
mediated destruction by the host. However, when the
cellular immune function is disturbed, EBV can cause lym-
phoproliferative diseases, such as lymphomas.
Small non-coding microRNAs (miRNAs) are key cellu-
lar regulatory elements and play critical roles in a variety
of cell signaling pathways [3]. MiRNAs are single-stranded
RNAs (ssRNAs) (approximately 18–25 nucleotides) which
regulate gene expression at the post-transcriptional level
by base pairing with target mRNAs, leading to mRNA
cleavage or translational repression. EBV was the first
virus demonstrated to encode miRNAs, including 44 ma-
ture miRNAs encoded by two primary transcripts (BHRF1
and BART) [4]. Many studies [5] have demonstrated
that EBV-miRNAs target viral and cellular genes which
influence the immune response and contribute to EBV-
induced malignancy. For example, miR-BHRF1-3 [6] tar-
gets the interferon (IFN)-inducible T-cell-attracting che-
mokine (CXCL11) which contributes to the survival of
infected cells. Nachmani et al. [7] also reported that miR-
BART2-5p could target MICB, a stress-induced natural
killer (NK) cell ligand, and allowed EBV-infected cells to
escape recognition. EBV infection can also alter the ex-
pression of cellular miRNAs during EBV infection which
are capable of regulating the immune response, apoptosis,
proliferation, and cellular differentiation [8]. Some studies
[9] have found that miR-155 and miR-21 of B cells were
induced in EBV infection, thus potentially play a role in
viral tumorigenesis.
Nevertheless, EBV and cellular miRNAs are differen-
tially expressed in many diseases [10, 11]. A previous
study [12] showed that BHRF1 miRNAs were expressed at
high levels in cells of type III EBV latency (such as IM),
but lower in type I and II EBV latency. While BART miR-
NAs were observed in all latent infection types and
expressed at high levels in type II EBV latency, such as
nasopharyngeal carcinoma (NPC). Cameron et al. [13]
demonstrated that the levels of has-miR-21, miR-23a,
miR-24, miR-27a, miR-34a, miR-146a/b, and miR-155
were higher in type III EBV latency cells than in type I
latency cells. Whereas, miR-28 expression was lower in
type III latency. For instance, in Hodgkin’s lymphoma,
hsa-miR-155, −21, −20a, −9, −16, and −429, were up-
regulated, while BHRF1 miRNAs and hsa-miR-200a were
down-regulated [14, 15]. Determining the expression pro-
file and dynamic changes of viral and cellular miRNAs in
IM with primary EBV infection is a fundamental and im-
portant aspect in investigating the pathogenic mechanism
of EBV-associated diseases. However, relatively little is
known about the dynamic expression of miRNAs during
primary EBV infection. To address this gap, ours’ is
the first study that describes the dynamic expression
of viral and cellular miRNAs in IM caused by primary
EBV infection.
Results
Levels of viral loads in plasma and PMBCs
The viral loads in plasma and PBMC of patients were
detected at days 0, 7, and 14 respectively. In plasma, the
average viral loads at days 0, 7, and 14 were 1.92 × 104
copies/mL (range 1.52 × 103-6.84 × 104 copies/mL), 9.63 ×
102 copies/mL (range 5.2 × 102-1.63 × 103 copies/mL), and
negative for all, respectively. Viral loads of plasma de-
creased sharply and were not detected at day 14 (Fig. 1a).
In detecting the viral loads in four types of lymphocytes at
day 0, B cells showed the highest viral loads (median
1.02 × 103 copies/μg DNA, range 5.13 × 102-1.75 × 103
copies/μg DNA) while there were no detectable viral loads
in the other lymphocyte subpopulations. This indicated
that B cells were the main target cells in IM. The average
viral loads in B cells at day 7 and day 14 were 8.35 × 102
copies/μg DNA (range 5.13 × 102-1.75 × 103 copies/μg
DNA) and 6.88 × 102 copies/μg DNA (range 3.7 × 102-
1.2 × 103 copies/μg DNA), respectively. Virus loads de-
creased in B cells more slowly than in plasma (Fig. 1b).
The viral loads in plasma and B cells of control group
subjects were undetectable.
Kinetic analysis of expression of EBV-miRNAs in plasma
and B cells
Forty four EBV-miRNAs were quantified by real-time
RT-PCR in plasma and B cells in IM patients at days 0, 7,
and 14 and healthy control group. Only 11 EBV-miRNAs
were detected in the control group (Fig. 2a). As B cells
were also analyzed in the control group, the viral loads
were less than 5 × 102 copies/μg. At day 0 of patients with
IM, nearly all of the EBV-miRNAs expressed in high
level except miR-BART2-3P, miR-BART10*-1 and miR-
BART20-3p (Fig. 2b). The higher levels of EBV-miRNAs
in plasma were miR-BHRF1-1, 1-2-3P, miR-BART13-1,
19-3p, 11-3P, 12–1, 16–1, and 4-5P. The expression pro-
files of EBV-miRNAs of B cells were similar to those of
plasma (Fig. 3). Compared with control group, all the
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Fig. 2 The expression profile of EBV-miRNAs in plasma. a The expression profile of EBV-miRNAs in plasma of control group; b The expression
profile of EBV-miRNAs in plasma of patients with IM at day 0
Fig. 1 Kinetic analysis of viral loads in patients with IM at day 0 (n = 15), day 7 (n = 15), and day 14 (n = 15). a The levels of viral loads in plasma
at different time-points. b The levels of viral loads in B cells at different time-points
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miRNAs except miR-BART2-3P, 20-3p, and 21-5p in-
creased and were significantly different at day 0 (Fig. 4).
The expression profile of most EBV-miRNAs in plasma
decreased at day 7 and day 14, especially the miR-BHRF1
cluster. At day 7 and day 14, miR-BHRF1-2-3P, 1–3, miR-
BART17-3p-1, 6-5p, 21-5p, 18-5p-1, 7-5p, 8-5p, 9-5p, 11-
5p-1, 20-5p, and 14*-1 were not detected. Additionally the
other EBV-miRNAs were expressed at lower levels at day
14 than day 7. Comparing the expression profile of EBV-
miRNAs among different times showed that miR-BHRF1-
Fig. 3 Comparison of the expression profile of EBV-miRNAs in B cells and plasma in patients with IM. All the data were are shown as mean ± standard
deviation for the samples
Fig. 4 Comparison of the expression profile of EBV-miRNAs in plasma of patients at day 0 (n = 15), day 7 (n = 15), and day 14 (n = 15), and healthy
controls group (n = 15). Data represents the mean ± standard deviation for the samples. a Comparison of the miR-BHRF1 cluster among the four
groups. b Comparison of the miR-BART cluster1 among the four groups. c Comparison of the miR-BART cluster2 among the four groups.
d Comparison of BART2-miRNA among the four groups. *P < 0.05 was considered statistically significant
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1, 1-2-3P, 1-2-5P, 1–3, miR-BART3-3P, 3-5P, 5-3P, 5-5P,
15-1(15), 17-3P, 17-5P, 7-3P, 7-5p, 9-3P, 9-5p, 11-5P, 14-
3p, 14-5P, and 2-5P were significantly different (Fig. 4).
The dynamic changes of expression profiles of EBV-
miRNAs in B cells were similar to those of in plasma at
day 7 and day 14.
With time progression, the levels of most EBV-miRNAs
and viral loads in plasma and B cells both decreased, but
the former decreased at a slower rate. Analyzing the
correlation of viral loads and EBV-miRNAs in plasma, we
found that there was a significant positive correlation
between viral loads and some EBV-miRNAs (miR-BHRF1-
2-3p, miR-BHRF1-2-5p, miR-BHRF 1–3, miR-BART2-5p,
miR-BART3-5p, miR-BART5-5p, miR-BART17-3p, miR-
BART6-3p, miR-BART6-5p, miR-BART21-5p, miR-BAR
T7-3p, miR-BART7-5p, miR-BART8-5p, miR-BART12-1,
miR-BART19-3p, miR-BART20-5p, miR-BART13*-1 and
miR-BART14*-1; 0.85 ≤ r ≤ 0.99, P < 0.05).
Human immunopathology and cell differentiation
associated miRNAs in B cells
To investigate the dynamic changes of cellular miRNAs in
primary infection in B cells, we profiled the expression
of 84 immunopathology and 84 cell differentiation-
associated miRNAs in B cells of IM patients at days
0, 7, and 14 and control group respectively. Forty cel-
lular miRNAs of day 0 were up-regulated more than
2-fold compared to the control group, for example
hsa-miR-134-5p, −18b-5p, −34a-5p, and -196a-5p,
−155-5p, −181a-5p, −142-5p; while 6 cellular miRNAs, in-
cluding hsa-miR-9-5p, −223-3p, −122-5p, −22-3p, −137,
and -219a-5p were down-regulated more than 2-fold (See
Figs. 5 and 6). Moreover, nearly all of these human miRNAs
increased at day 7 and day 14, including hsa-miR-134-5p,
−18b-5p, −34a-5p, and -196a-5p (See Figs. 5 and 6).
Additionally, hsa-miR-146a was up-regulated later more
than 2-fold. These cellular miRNAs were likely associated
with immunopathology and differentiation which may
play roles in the transition from resting to proliferating B
cells. The results showed that EBV loads had negative
correlation with hsa-miR-137 (r = −0.99, P < 0.05) and
hsa-miR-219a-5p of B cells (r = −0.97, P < 0.05).
Human immunopathology cellular miRNAs in CD8+ T cells
Eighty four human immunopathology associated miRNAs
in CD8+ T cells were detected in patients with IM at days
0, 7, and 14 and control group respectively. At day 0, 55
miRNAs were down-regulated, including hsa-let-7a-5p,
hsa-miR-9-5p, −223-3p, −135a-5p, −135b-5p, −142-3p,
−142-5p, 146a-5p, and −155-5p, while 20 miRNAs were
up-regulated, including hsa-miR-134-5p, −147a, −149-5p,
−18b-5p, −205-5p, hsa-miR-206, −210-3p, and -34a-5p
(See Fig. 7). At day 7 and day 14, most of the cellular miR-
NAs of CD8 + T cells, including hsa-let-7a-5p, −142-3p,
−142-5p, and −155-5p, decreased with time (See Fig. 8).
The results showed that EBV loads had positive cor-
relation with hsa-miR-302a-3p of CD 8 + T cells (r = 0.91,
P < 0.05).
Correlation of the levels of EBV-miRNAs and cellular miRNAs
Comparing the relationship between cellular miRNAs
and EBV-miRNAs, we determined that hsa-miR-18b-5p
of CD8+ T cells exhibited positive correlation with
BHRF1-2-5P, BART2-5P, 4-3p, 4-5p, 16–1, 6-3p, 22, 12–1,
19-3P, 19-5P, 13–1, and 13*-1 (0.96 ≤ r ≤ 0.99, P < 0.05).
Hsa-miR-155-5p of B cells had positive correlation with
BHRF1-1, 1-2-5P, BART2-5P, 3-3p, 4-3p, 4-5p, 1-3P-1, 1-
5P-1, 22, 12–1, 13–1, and 13*-1 (0.97 ≤ r ≤ 0.99, P < 0.05).
Additionally hsa-miR-181a-5p of B cells had positive
correlation with BART4-3p, 4-5P, 16–1, 22, 10–1, 12–1,
Fig. 5 The fold change of top 23 gradually up-regulated and down-regulated cellular immunopathology-associated miRNAs (>2.0 fold) in B cells.
Comparing the patients at day 0 (n = 15), day 7 (n = 15), and day 14 (n = 15) with healthy control group (n = 15). *P < 0.05 was considered
statistically significant
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19-3P, 19-5P, 20-3p, 13–1, and 13*-1 (0.97 ≤ r ≤ 0.99,
P < 0.05).
Discussion
This is the first study that describes the dynamic expres-
sion profile of viral and cellular miRNAs in IM with pri-
mary EBV infection. In the early phase, nearly all of the
EBV-miRNAs were expressed at high levels, especially
miR-BHRF1-1, 1-2-3P, and miR-BART13-1. Cai et al. [4]
previously demonstrated that both BHRF1 and BART
miRNAs were expressed during primary EBV infection,
but BHRF1 miRNAs were expressed at higher levels than
BART miRNAs, which is consistent with the results of this
study. The increased levels of BHRF1 and BART-derived
miRNAs during acute phase of infection were likely due
to their location. Feederle et al. [16] showed that miR-
BHRF1-2 and −3 are located in the 3’UTR of the early
lytic protein BHRF1. Using EBV-infected cells in vitro,
Amoroso et al. [17] showed that BHRF1-2 and 1–3 miR-
NAs increased as early as 24 h after the onset of lytic
infection, but BHRF1-1 increased until 48 h or later. How-
ever, in our study, miR-BHRF1-1 increased higher than
miR-BHRF1-2 and 1–3, which might be due to the pa-
tients being in different phases of infection. Seto et al. [18]
demonstrated that elevated BHRF1 cluster of miRNAs
inhibited apoptosis of infected B cells during primary EBV
infection. Therefore, elevated expression of miR-BHRF1 in
IM as shown in our study indicated that it might contrib-
ute to proliferation of infected B cells. Xia et al. [6] have
shown that miR-BHRF1-3 can target CXCL11 which con-
tributes to B cell transformation and immune evasion by
modulating host cytokine networks.
Over time, BHRF1 miRNAs decreased or even un-
detected, but miR-BART13-1, 11-3p-1, 16–1, and 19-3p
Fig. 6 The fold change of top 23 gradually up-regulated and down-regulated cellular differentiation-associated miRNAs (>2.0 fold) in B cells.
Comparing the patients at day 0 (n = 15), day 7 (n = 15), and day 14 (n = 15) with healthy control group (n = 15). *P < 0.05 was considered
statistically significant
Fig. 7 The fold change of top 75 gradually up-regulated and down-regulated cellular immunopathology-associated miRNAs in CD8+ T cells at
day 0 of patients with IM (n = 15) compared with control group (n = 15). *P < 0.05 was considered statistically significant
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were expressed at relatively high rates. Thus, in later
phase of infection, BART miRNAs may play important
roles in EBV infection maintenance. Cameron et al. [14]
showed that most of the BART miRNAs were essential
for B cell transformation. Riley et al. [19] showed that
BART13-3p could target CAPRIN2, a Wnt signaling en-
hancer whose over-expression enhances apoptosis, and
can maintain EBV persistence during latent infection in
B cells. BART16 and BART1-3p targeted caspase-3 that
block or inhibit apoptosis [20]. Ross [21] demonstrated
that miR-BART11-5p could target early B cell factor
(EBF1) which plays roles in B cell transformation. At
different times of infection, the profile patterns of EBV-
miRNAs in plasma were similar in EBV-infected B cells
in our study, as was previously demonstrated by a previ-
ous study [22].
In this study, EBV DNAs were not detected in plasma
at day 14, yet some EBV-miRNAs were detected at the
same time-point. A previous study [23] demonstrated
that mature EBV-miRNAs are secreted by EBV-infected
B cells through exosomes. And exosomes can protect
EBV-miRNAs from degradation by RNases. This poten-
tially explains why some patients with higher EBV-
miRNAs did not have measurable EBV DNA loads in
plasma. This also implied that EBV-miRNAs were more
stable, and it could be used as potential markers for diag-
nosis and treatment for EBV associated diseases. Kawano
et al. [24] pointed out that the levels of miR-BART2-5p, 13,
and 15 in plasma correlated with the severity and progno-
sis of CAEBV. Zhou et al. [25] found that levels of several
EBV-miRNAs (miR-BART3-3p, 3-5p, 1-3p, 1-5p, 15–1, 5-
3p, and 16–1 et al.) in Epstein-Barr virus-associated hemo-
phagocytic lymphohistiocytosis (EBV-HLH) were higher
than in IM and healthy controls, and suggested that plasma
miR-BART16-1 could be a potential biomarker for moni-
toring EBV-HLH progression.
Fig. 8 The fold change of immunopathology-associated miRNAs in CD8+ T cells among patients at day 0 (n = 15), day 7 (n = 15), and day 14
(n = 15) compared with healthy control group (n = 15). a The up-regulated cellular miRNAs at different times. b The down-regulated cellular
miRNAs at different times
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Besides encoding its own viral miRNAs, EBV infection
also affects the expression of cellular miRNAs which are
able to regulate the proliferation and differentiation of B
and T cells [8]. Our study first investigated the dynamic
expression of cellular miRNAs in B cells and CD8 + T
cells of IM. In the early time-point after EBV infection,
there was dramatic up-regulation of immunopathology
and differentiation-associated cellular miRNAs of B cells,
such as miR-155-5p, −34a-5p, and -18b-5p, −210-3p,
−301a-3p, −302c-3p, −miR-7-5p, −181a-5p, and −142-
5p. Cameron et al. [13] also point out that the expres-
sion of has-miR-155 and miR-34a in type III EBV la-
tency cells was higher. With time, the expressions of
nearly all of these cellular miRNAs increased, and were
associated with immunopathology and differentiation
which may play roles in the transition from resting to
proliferating B cells. Forte et al. [26] reported that over-
expression of miR-34a in EBV-driven B cells contributed
to the proliferation of these B cells. Linnstaedt et al. [27]
showed that miR-155 played a role in B cell develop-
ment and differentiation and was up-regulated in various
EBV associated B cell lymphomas. Zhang et al. [28]
showed that over-expression of miR-181a facilitated B
cell differentiation. Therefore, in our study, the expres-
sion of miR-34a, miR-155, and miR-181a were elevated
in primary EBV infection which may contribute to B cell
differentiation and proliferation. Zhang et al. [28] also
found that the expression of miR-30 family and miR-9
were elevated in GC B cells and these miRNAs could
target B lymphocyte-induced maturation protein 1
(BLIMP1), which is a gene important for B cell differen-
tiation. However in our study, has-miR-9 decreased in
peripheral B cells of IM which may be different from
GC B cells.
However, in CD8 + T cells, various immunopathology-
associated cellular miRNAs were down-regulated. In our
study, has-miR-142, −223, −29c-3p, −181a, −200a-3p,
−195-5p, let-7a-5p, −7c-5p, −7 g-5p, and −155-5p were
down-regulated. Previous studies [29, 30] also demon-
strated that the levels of has-miR-29, −142, −let-7, and
-181a in effector CD8+ T cells were significantly down
regulated. Over time, most of the cellular miRNAs de-
creased. Previous study [31] showed that miR-181a
could reduce the numbers of circulating T lymphocytes
and affect the differentiation of T lymphocytes, as well
as disrupt distribution of CD4+ and CD8+ T cells. In
our study, we found that the expression of miR-181a
was down-regulated at the early phase of infection, and
was different from B cells, which may contribute to the
expansion of CD8+ T cells. In addition to the modula-
tion of T lymphocyte differentiation, miRNAs have been
demonstrated to regulate T cell activation. A previous
study [32] showed that miR-181a could alter the T cell
threshold and sensitivity to antigens. Some studies [27]
also demonstrated that over-expression of miR-142-3p
and miR-142-5p in T cells may be key mediators of cel-
lular signaling and can regulate immune function. This
could protect infected B cells from being killed and
enter into latent infection.
Additionally, our study showed that hsa-miR-18b-5p
of CD8+ T cells had positive correlation with BHRF1-
2-5P and BART2-5P. Hsa-miR-155-5p of B cells had
positive correlation with BHRF1-1, while hsa-miR-
181a-5p of B cells had positive correlation with
BART16-1 and BART22. Further research on the
roles of EBV-miRNAs and cellular miRNAs will pro-
vide new insights into the complex gene regulation
network.
Conclusions
Viral and cellular miRNAs play important roles in the
pathogenesis of diseases associated with EBV infection
[19]. The expression profile of viral and cellular miRNAs
in IM with primary EBV infection were first described in
this study. These results provide the basis of investigat-
ing the pathogenic mechanism of EBV-related diseases
and bring new insights into the diagnosis and treatment
these diseases. However, the potential gene targets of




Fifteen patients (8 males and 7 females) with IM, aged
from 1 year and 10 months old to 11 years old (median
age, 5 years and 4 months old), were enrolled in this
study. IM was defined according to the following previ-
ously proposed criteria [33]: (1) presence of at least three
of the following clinical manifestations: fever, pharyn-
gitis, cervical lymphadenopathy, hepatomegaly or
splenomegaly; (2) serologic profile of primary EBV infec-
tion: IgM to EBV viral capsid antigen (VCA-IgM) and
IgG to EBV capsid antigen (VCA-IgG) were positive,
with absence of an antibody to Epstein-Barr nuclear
antigen (EBNA). Within the patient group, 2 mL periph-
eral blood of each patient were obtained at three differ-
ent time points, including days 0, 7, and 14. Day 0 was
defined as the admission day for IM patients, while
7 days later and 14 days later were defined as day 7 and
day 14 respectively. Fifteen healthy children who were
seropositive for EBV were enrolled as control group.
The study design was in accordance with the Helsinki
Declaration and was approved by the Beijing Children’s
Hospital Ethics Committee. Informed consent was ob-
tained from the parents or legal guardians of the
pediatric participants.
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Sample collection and cell isolation
Two mL peripheral blood sample of patients was col-
lected into an EDTA-containing tube, and centrifuged to
isolate plasma and peripheral blood mononuclear cells
(PBMCs) using the Lymphocyte Separation Medium
(Sigma, MO, USA). Then the PBMCs were fractionated
into CD8+, CD19+, CD4+, and CD56+ cells by means of
IMag (BD Biosciences). The purity of each PBMC sub-
population in our system was typically >95 % as assessed
by flow cytometry analysis.
Quantification of viral load in plasma and determination
of EBV-infected cells
EBV DNA was extracted from 200 μL of plasma using
QIAamp® MinElute® Virus Spin Kit and from four types
of lymphocytes (1 × 105 cells) using a QIAmp DNA Mi-
cro Kit (Qiagen) following the manufacturer’s instruc-
tions. The viral loads were detected by LightCycler480®
real-time quantitative PCR (qPCR) using a commercial
EBV DNA Quantitative kit (Daan, Guangzhou, China)
and viral load of ≥ 5 × 102 particles was considered posi-
tive. Viral loads in plasma and cell samples were respect-
ively expressed as copies per milliliter and copies per
microgram of DNA. The target cells showed the highest
viral loads.
RNA extraction and detection of EBV miRNA from plasma
and B cells by quantitative real-time PCR (qPCR)
Total RNA was carefully extracted from 200 μL of
plasma or 1 × 105 B cells of patients with IM and control
subjects by using miRNeasy serum/plasma kit (Qiagen)
and miRNeasy mini kit (Qiagen) respectively according
to the manufacturer’s protocol. In plasma samples, C.
elegans miR-39 miRNA mimic (Qiagen) was “spiked-in”
at the early stage of RNA extraction as a mimic refer-
ence. The miScript II RT Kit (Qiagen) was used to
synthesize cDNA. Then a miScript SYBR Green PCR kit
(Qiagen) was used for the relative quantitation of 44
EBV-miRNAs according to the manufacturer’s protocol
and the miScript primers specific to the corresponding
mature sequence obtained from miRBase (www.miRBase.
org), including four miR-BHRF1 (miR-BHRF1-1, 1-2-3P,
1-2-5P, 1–3), 14 miR-BART cluster 1(miR-BART1-3P, 1-
5P, 3-3P, 3-5P, 4-3P, 4-5P, 5-3P, 5-5P, 6-3P, 6-5P, 15-1(15),
16-1(16), 17-3P, 17-5P), 24 miR-BART cluster 2(7-3P, 7-
5p, 8-3P, 8-5p, 9-3P, 9-5p, 10-1(10-3P), 10*-1(10-5P),
11-3p, 11-5P, 12-1(12), 13-1(13-3P), 13*-1(13-5P), 14-
3p, 14-5P, 18-3p, 18-5p, 19-3p, 19-5p, 20-3p, 20-5p,
21-3p, 21-5p, 22) and two miR-BART2 (miR-BART2-
3P, 2-5P). Amplification reactions then were perfor-
med by the LightCycler480 System (Roche Diagnosis,
Mannheim, Germany) under the following conditions;
15 min initial hold at 95 °C, 40 cycles of 94 °C for 15 s,
55 °C for 30 s, 70 for 30 s. Data from quantitative RT-PCR
were analyzed using the comparative threshold cycle (Ct)
method. For all plasma samples, C. elegans miR-39
(Qiagen) was used as the endogenous reference, but for all
the samples of cells, cell-derived U6 snRNA (Qiagen) was
used as the endogenous reference to normalize the relative
expression of EBV-miRNAs. ΔCt was given as the Ct of
difference between the target miRNA and the endogenous
control. The amount of miRNAs was given by the arith-
metic formula 2ΔCt. Note that relative expression levels
are by definition values without units.
Detection of human cellular miRNA from B cells and
CD8 + T cells
Total RNA was extracted from 1 × 105 B and CD8+ T cells
from the patients and the controls by a miRNeasy mini kit
(Qiagen) according to the manufacturer’s protocol. A real
time quantitative PCR assay was performed as described
above. Eighty four human immunopathology (Table 1) as-
sociated miRNAs in B cells and CD8+ Tcells were analyzed
using Human Immunopathology miScript miRNA PCR
Array (QIAGEN, MIHS-104Z). Eighty four human cell dif-
ferentiation (Table 2) associated miRNAs in B cells were
analyzed using Cell Differentiation & Development miRNA
PCR Array (QIAGEN, MIHS-103Z). U6 was used as the
endogenous reference. Data analyses were performed with
the web-based software package for the RT2 Profiler PCR
Table 1 84 Human immunopathology associated miRNAs
hsa-let-7a-5p hsa-let-7c-5p hsa-let-7d-5p hsa-let-7e-5p
hsa-let-7g-5p hsa-miR-103a-3p hsa-miR-105-5p hsa-miR-125a-5p
hsa-miR-125b-5p hsa-miR-126-3p hsa-miR-128-3p hsa-miR-130a-3p
hsa-miR-132-3p hsa-miR-134-5p hsa-miR-135a-5p hsa-miR-135b-5p,
hsa-miR-138-5p hsa-miR-142-5p hsa-miR-142-3p hsa-miR-143-3p
hsa-miR-145-5p hsa-miR-146a-5p hsa-miR-147a hsa-miR-148a-3p
hsa-miR-149-5p hsa-miR-150-5p hsa-miR-152-3p hsa-miR-155-5p
hsa-miR-15a-5p hsa-miR-15b-5p hsa-miR-16-5p hsa-miR-17-5p
hsa-miR-181a-5p hsa-miR-182a-5p hsa-miR-183-5p hsa-miR-184
hsa-miR-185a-5p mi-186a-5p hsa-miR-187-3p hsa-miR-18a-5p
hsa-miR-18b-5p hsa-miR-191-5p hsa-miR-194-5p hsa-miR-195-5p
hsa-miR-196a-5p hsa-miR-19a-3p hsa-miR-19b-3p hsa-miR-200a-3p
hsa-miR-203a-3p hsa-miR-205-5p hsa-miR-206 hsa-miR-20a-5p
hsa-miR-20b-5p hsa-miR-21-5p hsa-miR-210-3p hsa-miR-214-3p
hsa-miR-223-3p hsa-miR-23b-3p hsa-miR-26a-5p hsa-miR-26b-5p
hsa-miR-27a-3p hsa-miR-27b-3p hsa-miR-298 hsa-miR-299-3p
hsa-miR-29b-3p hsa-miR-29c-3p hsa-miR-302a-3p hsa-miR-30b-5p
hsa-miR-30c-5p hsa-miR-30e-5p hsa-miR-31-5p hsa-miR-325
hsa-miR-335-5p hsa-miR-34a-5p hsa-miR-363-3p hsa-miR-379-5p
hsa-miR-383-5p hsa-miR-409-3p hsa-miR-451a hsa-miR-493-3p
hsa-miR-574-3p hsa-miR-9-5p hsa-miR-98-5p hsa-miR-99b-5p
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Array Data Analysis (http://www.Sabiosciences.com/pcr/
arrayanalysis.php).
Fold-Change (2^(− Delta Delta Ct)) was the normal-
ized gene expression (2^(− Delta Ct)) in the test sample
divided the normalized gene expression (2^(− Delta Ct))
in the control sample. Fold-regulation represented fold-
change results in a biologically meaningful way. Fold-
change values greater than two indicated a positive- or
an up-regulation, and the fold-regulation was equal to
the fold-change. Fold-change values less than two indicated
a negative or down-regulation, and the fold-regulation
was the negative inverse of the fold-change. A p-value
<0.05 was considered to be statistically significant.
Statistical analysis
Statistical analysis was performed using SPSS 19.0 soft-
ware (SPSS). The Mann–Whitney U test and Wilcoxon
signed rank test were used for comparisons of two
groups of patients. For comparisons of three groups, the
Mann–Whitney U test with the Bonferroni correction
was used. Pearson correlation coefficient analysis was
used to assess the correlation of the expression levels of
miRNAs and numbers of EBV DNA copy and lympho-
cytes. According to the relative expression of EBV-positive
miRNAs in the EBV-negative cell line Ramos, 2−12 was de-
fined as the cut off value. Differences with P values <0.05
were deemed to be statistically significant.
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Table 2 84 Human cell differentiation associated miRNAs
hsa-miR-106b-5p hsa-let-7e-5p hsa-miR-20b-5p hsa-miR-125a-5p
hsa-miR-125b-5p hsa-miR-122-5p hsa-miR-155-5p hsa-miR-126-3p
hsa-miR-22-3p hsa-miR-92a-3p hsa-miR-141-3p hsa-miR-378a-3p
hsa-miR-10a-5p hsa-miR-182-5p hsa-miR-302a-3p hsa-miR-93-5p
hsa-miR-1-3p hsa-miR-181a-5p hsa-miR-146b-5p hsa-let-7f-5p
hsa-miR-196a-5p hsa-miR-301a-3p hsa-miR-488-3p hsa-miR-215-5p
hsa-miR-24-3p hsa-miR-192-5p hsa-miR-18a-5p hsa-miR-100-5p
hsa-miR-9-5p hsa-miR-137 hsa-miR-15a-5p hsa-miR-134-5p
hsa-miR-103a-3p hsa-miR-424-5p hsa-miR-20a-5p hsa-let-7i-5p
hsa-miR-222-3p hsa-miR-99a-5p hsa-miR-206 hsa-miR-195-5p
hsa-miR-132-3p hsa-miR-16-5p hsa-miR-23b-3p hsa-miR-214-3p
hsa-miR-21-5p hsa-miR-18b-5p hsa-miR-345-5p hsa-let-7c-5p
hsa-miR-26a-5p hsa-miR-101-3p hsa-miR-17-5p hsa-miR-129-5p
hsa-miR-96-5p hsa-miR-183-5p hsa-miR-210-3p hsa-miR-223-3p
hsa-let-7a-5p hsa-miR-518b hsa-miR-194-5p hsa-miR-218-5p
hsa-let-7d-5p hsa-miR-205-5p hsa-miR-10b-5p hsa-miR-185-5 p
hsa-miR-133b hsa-miR-520 g-3p hsa-miR-33a-5p hsa-miR-124-3p
hsa-miR-208a-3p hsa-miR-142-5p hsa-miR-150-5p hsa-miR-128-3p
hsa-miR-15b-5p hsa-miR-130a-3p hsa-miR-127-5p hsa-miR-498
hsa-let-7b-5p hsa-miR-302c-3p hsa-miR-219a-5p hsa-let-7g-5p
hsa-miR-375 hsa-miR-7-5p hsa-miR-146a-5p hsa-miR-142-3p
Gao et al. Virology Journal  (2015) 12:208 Page 10 of 11
Received: 17 September 2015 Accepted: 30 November 2015
References
1. Balfour Jr HH, Dunmire SK, Hogquist KA. Infectious mononucleosis.
Clin Transl Immunology. 2015;4:e33.
2. Balfour Jr HH, Odumade OA, Schmeling DO, Mullan BD, Ed JA, Knight JA, et
al. Behavioral, virologic, and immunologic factors associated with
acquisition and severity of primary Epstein-Barr virus infection in university
students. J Infect Dis. 2013;207:80–8.
3. Cullen BR. MicroRNAs as mediators of viral evasion of the immune system.
Nat Immunol. 2013;14:205–10.
4. Cai X, Schafer A, Lu S, Bilello JP, Desrosiers RC, Edwards R, et al. Epstein-Barr
virus microRNAs are evolutionarily conserved and differentially expressed.
PLoS Pathog. 2006;2:e23.
5. Kuzembayeva M, Hayes M, Sugden B. Multiple functions are mediated by
the miRNAs of Epstein-Barr virus. Curr Opin Virol. 2014;7:61–5.
6. Xia T, O'Hara A, Araujo I, Barreto J, Carvalho E, Sapucaia JB, et al. EBV
microRNAs in primary lymphomas and targeting of CXCL-11 by
ebv-mir-BHRF1-3. Cancer Res. 2008;68:1436–42.
7. Nachmani D, Stern-Ginossar N, Sarid R, Mandelboim O. Diverse herpesvirus
microRNAs target the stress-induced immune ligand MICB to escape
recognition by natural killer cells. Cell Host Microbe. 2009;5:376–85.
8. Belver L, Papavasiliou FN, Ramiro AR. MicroRNA control of lymphocyte
differentiation and function. Curr Opin Immunol. 2011;23:368–73.
9. Imig J, Motsch N, Zhu JY, Barth S, Okoniewski M, Reineke T, et al. microRNA
profiling in Epstein-Barr virus-associated B-cell lymphoma. Nucleic Acids Res.
2011;39:1880–93.
10. Pratt ZL, Kuzembayeva M, Sengupta S, Sugden B. The microRNAs of
Epstein-Barr Virus are expressed at dramatically differing levels among cell
lines. Virology. 2009;386:387–97.
11. Skalsky RL, Corcoran DL, Gottwein E, Frank CL, Kang D, Hafner M, et al. The
viral and cellular microRNA targetome in lymphoblastoid cell lines. PLoS
Pathog. 2012;8:e1002484.
12. Yang HJ, Huang TJ, Yang CF, Peng LX, Liu RY, Yang GD, et al.
Comprehensive profiling of Epstein-Barr virus-encoded miRNA species
associated with specific latency types in tumor cells. Virol J. 2013;10:314.
13. Cameron JE, Fewell C, Yin Q, McBride J, Wang X, Lin Z, et al. Epstein-Barr
virus growth/latency III program alters cellular microRNA expression.
Virology. 2008;382:257–66.
14. Vereide DT, Seto E, Chiu YF, Hayes M, Tagawa T, Grundhoff A, et al. Epstein-
Barr virus maintains lymphomas via its miRNAs. Oncogene. 2014;33:1258–64.
15. Lin Z, Wang X, Fewell C, Cameron J, Yin Q, Flemington EK. Differential
expression of the miR-200 family microRNAs in epithelial and B cells and
regulation of Epstein-Barr virus reactivation by the miR-200 family member
miR-429. J Virol. 2010;84:7892–7.
16. Feederle R, Haar J, Bernhardt K, Linnstaedt SD, Bannert H, Lips H, et al. The
members of an Epstein-Barr virus microRNA cluster cooperate to transform
B lymphocytes. J Virol. 2011;85:9801–10.
17. Amoroso R, Fitzsimmons L, Thomas WA, Kelly GL, Rowe M, Bell AI.
Quantitative studies of Epstein-Barr virus-encoded microRNAs provide novel
insights into their regulation. J Virol. 2011;85:996–1010.
18. Seto E, Moosmann A, Gromminger S, Walz N, Grundhoff A, Hammerschmidt
W. Micro RNAs of Epstein-Barr virus promote cell cycle progression and
prevent apoptosis of primary human B cells. PLoS Pathog. 2010;6:e1001063.
19. Riley KJ, Rabinowitz GS, Yario TA, Luna JM, Darnell RB, Steitz JA. EBV and
human microRNAs co-target oncogenic and apoptotic viral and human
genes during latency. EMBO J. 2012;31:2207–21.
20. Dolken L, Malterer G, Erhard F, Kothe S, Friedel CC, Suffert G, et al.
Systematic analysis of viral and cellular microRNA targets in cells latently
infected with human gamma-herpesviruses by RISC immunoprecipitation
assay. Cell Host Microbe. 2010;7:324–34.
21. Ross N, Gandhi MK, Nourse JP. The Epstein-Barr virus microRNA BART11-5p
targets the early B-cell transcription factor EBF1. Am J Blood Res.
2013;3:210–24.
22. Gourzones C, Gelin A, Bombik I, Klibi J, Verillaud B, Guigay J, et al.
Extra-cellular release and blood diffusion of BART viral micro-RNAs
produced by EBV-infected nasopharyngeal carcinoma cells. Virol J.
2010;7:271.
23. Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, van Eijndhoven MA,
Hopmans ES, Lindenberg JL, et al. Functional delivery of viral miRNAs via
exosomes. Proc Natl Acad Sci U S A. 2010;107:6328–33.
24. Kawano Y, Iwata S, Kawada J, Gotoh K, Suzuki M, Torii Y, et al. Plasma viral
microRNA profiles reveal potential biomarkers for chronic active Epstein-Barr
virus infection. J Infect Dis. 2013;208:771–9.
25. Zhou C, Xie Z, Gao L, Liu C, Ai J, Zhang L, et al. Profiling of EBV-Encoded
microRNAs in EBV-Associated Hemophagocytic Lymphohistiocytosis.
Tohoku J Exp Med. 2015;237:117–26.
26. Forte E, Salinas RE, Chang C, Zhou T, Linnstaedt SD, Gottwein E, et al.
The Epstein-Barr virus (EBV)-induced tumor suppressor microRNA MiR-34a is
growth promoting in EBV-infected B cells. J Virol. 2012;86:6889–98.
27. Linnstaedt SD, Gottwein E, Skalsky RL, Luftig MA, Cullen BR. Virally induced
cellular microRNA miR-155 plays a key role in B-cell immortalization by
Epstein-Barr virus. J Virol. 2010;84:11670–8.
28. Zhang J, Jima DD, Jacobs C, Fischer R, Gottwein E, Huang G, et al. Patterns
of microRNA expression characterize stages of human B-cell differentiation.
Blood. 2009;113:4586–94.
29. Wu H, Neilson JR, Kumar P, Manocha M, Shankar P, Sharp PA, et al. miRNA
profiling of naive, effector and memory CD8 T cells. PLoS One. 2007;2:e1020.
30. Gracias DT, Stelekati E, Hope JL, Boesteanu AC, Doering TA, Norton J, et al.
The microRNA miR-155 controls CD8(+) T cell responses by regulating
interferon signaling. Nat Immunol. 2013;14:593–602.
31. Shivdasani RA. MicroRNAs: regulators of gene expression and cell
differentiation. Blood. 2006;108:3646–53.
32. Souza TA, Stollar BD, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. Influence
of EBV on the peripheral blood memory B cell compartment. J Immunol.
2007;179:3153–60.
33. Gao LW, Xie ZD, Liu YY, Wang Y, Shen KL. Epidemiologic and clinical
characteristics of infectious mononucleosis associated with Epstein-Barr
virus infection in children in Beijing. China World J Pediatr. 2011;7:45–9.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Gao et al. Virology Journal  (2015) 12:208 Page 11 of 11
